Literature DB >> 7035728

Reactivity of gastric cancer patients in leucocyte migration inhibition tests to 3M KCl extracts from gastric tumor.

O Kojima, A Oh, N Kitagawa, Y Uehara, B Nishioka, Y Fujita, S Majima.   

Abstract

Leucocytes from patients with gastric cancer and other malignant and non-malignant diseases of the gastrointestinal tract as well as from healthy controls were tested for leucocyte migration inhibition test (LMI) using five different, allogeneic 3M KCl soluble extracts from gastric cancer tissues. The normal range of migration index (MI) was considered to be between 0.77 and 1.18 by calculating the mean MI +/- 2SD of ten healthy controls with cancer extracts. MIs out of this range were considered to be pathologic. In LMI test with a single tumor extract, pathologic MI was found in 48% of 79 gastric cancer patients, such being significantly higher than in those (4-21%) of three other groups of patients. In the panel mode of LMI, i.e., testing each blood sample with five different tumor extracts, 79% (62/79) of patients with gastric cancer were reactive, while 25% (5/20) of colorectal cancer patients showed "positive" reaction and no "positive" reactivity was observed in two other groups of patients. Thus, the "positive" reactivity in patients with gastric cancer was observed significantly higher than those in the other 3 groups of patients. Gastric cancer extracts had a wide range of cross-reactivity when compared with colorectal tumor extracts which showed a relatively restricted cross-reactivity. Thus, the LMI tests, particularly when tested by a panel mode, seems to express cell-mediated immunity against tumor associated antigens of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7035728     DOI: 10.1007/bf02469024

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  24 in total

1.  Inhibition of human leukocyte migration in agarose by kcl extracts of carcinoma of the lung.

Authors:  A W Boddie; E C Holmes; J A Roth; D L Morton
Journal:  Int J Cancer       Date:  1975-05-15       Impact factor: 7.396

2.  Leukocyte migration inhibition in patients with Ewing's sarcoma by 3-M potassium chloride extracts of fresh and tissue-cultured Ewing's sarcomas.

Authors:  J L McCoy; L J Jerome; G B Cannon; T C Pomeroy; R J Connor; R K Oldham; J L Weese; R B Herberman
Journal:  J Natl Cancer Inst       Date:  1977-10       Impact factor: 13.506

3.  Migration enhancement factor: a new lymphokine.

Authors:  R H Weisbart; R Bluestone; L S Goldberg; C M Pearson
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

4.  The general rules for The gastric cancer study in surgery.

Authors: 
Journal:  Jpn J Surg       Date:  1973-03

5.  Cellular immunity in mammary cancer patients as measured by the leukocyte migration test (LMT). A follow-up study.

Authors:  K Rieche; A Arndt; G Pasternak
Journal:  Int J Cancer       Date:  1976-02-15       Impact factor: 7.396

6.  Autogenous leukocyte migration in human malignancies.

Authors:  E G Elias; L L Elias
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

7.  Inhibition of migration of human autogenous and allogeneic leukocytes by extracts of patients' cancers.

Authors:  W H Wolberg
Journal:  Cancer Res       Date:  1971-06       Impact factor: 12.701

8.  Inhibition of leucocyte migration by potassium chloride extracts of human tumor cells in ascites and from tissues.

Authors:  K Imai; Y Hosokawa; H Abe; A Yachi; T Wada
Journal:  Gan       Date:  1977-10

9.  Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanoma.

Authors:  J L McCoy; L F Jerome; J H Dean; E Perlin; R K Oldham; D H Char; M H Cohen; E L Felix; R B Herberman
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

10.  Postoperative depression of tumour-directed cell-mediated immunity in patients with malignant disease.

Authors:  A J Cochran; W G Spilg; R M Mackie; C E Thomas
Journal:  Br Med J       Date:  1972-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.